Advicenne S.A. (ALDVI.PA)
EUR 1.67
(0.12%)
EUR 1.67
(0.12%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 24.37 Million EUR | -2.0% |
| 2022 | 24.87 Million EUR | 33.94% |
| 2021 | 18.57 Million EUR | -10.42% |
| 2020 | 20.73 Million EUR | 245.8% |
| 2019 | 5.99 Million EUR | 69.15% |
| 2018 | 3.54 Million EUR | -30.59% |
| 2017 | 5.1 Million EUR | -39.26% |
| 2016 | 8.4 Million EUR | 80.8% |
| 2015 | 4.65 Million EUR | 230.26% |
| 2014 | 1.4 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 25.38 Million EUR | 4.14% |
| 2024 Q2 | 25.38 Million EUR | 0.0% |
| 2023 Q1 | 24.89 Million EUR | 0.08% |
| 2023 FY | 24.37 Million EUR | -2.0% |
| 2023 Q4 | 24.37 Million EUR | 0.0% |
| 2023 Q3 | 24.37 Million EUR | -2.08% |
| 2023 Q2 | 24.89 Million EUR | 0.0% |
| 2022 FY | 24.87 Million EUR | 33.94% |
| 2022 Q4 | 24.87 Million EUR | 0.0% |
| 2022 Q3 | 24.87 Million EUR | 37.96% |
| 2022 Q2 | 18.03 Million EUR | 0.0% |
| 2022 Q1 | 18.03 Million EUR | -2.91% |
| 2021 Q3 | 18.57 Million EUR | -5.41% |
| 2021 Q1 | 19.63 Million EUR | -5.3% |
| 2021 FY | 18.57 Million EUR | -10.42% |
| 2021 Q4 | 18.57 Million EUR | 0.0% |
| 2021 Q2 | 19.63 Million EUR | 0.0% |
| 2020 FY | 20.73 Million EUR | 245.8% |
| 2020 Q4 | 20.73 Million EUR | 0.0% |
| 2020 Q1 | 15.46 Million EUR | 158.0% |
| 2020 Q2 | 15.46 Million EUR | 0.0% |
| 2020 Q3 | 20.73 Million EUR | 34.03% |
| 2019 FY | 5.99 Million EUR | 69.15% |
| 2019 Q2 | 5.32 Million EUR | 0.0% |
| 2019 Q1 | 5.32 Million EUR | 50.26% |
| 2019 Q4 | 5.99 Million EUR | -16.25% |
| 2019 Q3 | 7.15 Million EUR | 34.42% |
| 2018 Q4 | 3.54 Million EUR | 0.0% |
| 2018 FY | 3.54 Million EUR | -30.59% |
| 2018 Q3 | 3.54 Million EUR | -20.49% |
| 2018 Q2 | 4.45 Million EUR | 0.0% |
| 2018 Q1 | 4.45 Million EUR | -12.69% |
| 2017 Q2 | 4.95 Million EUR | 0.0% |
| 2017 Q3 | 5.02 Million EUR | 1.45% |
| 2017 Q4 | 5.1 Million EUR | 1.68% |
| 2017 FY | 5.1 Million EUR | -39.26% |
| 2017 Q1 | 4.95 Million EUR | -41.12% |
| 2016 Q3 | 8.4 Million EUR | 0.0% |
| 2016 Q1 | - EUR | 0.0% |
| 2016 Q4 | 8.4 Million EUR | 0.0% |
| 2016 FY | 8.4 Million EUR | 80.8% |
| 2015 FY | 4.65 Million EUR | 230.26% |
| 2014 FY | 1.4 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ABIONYX Pharma SA | 6.91 Million EUR | -252.677% |
| ABIVAX Société Anonyme | 131.05 Million EUR | 81.399% |
| Adocia SA | 31.87 Million EUR | 23.511% |
| Aelis Farma SA | 13.08 Million EUR | -86.369% |
| Biophytis S.A. | 15.84 Million EUR | -53.808% |
| genOway Société anonyme | 14.45 Million EUR | -68.588% |
| IntegraGen SA | 5.97 Million EUR | -307.656% |
| Medesis Pharma S.A. | 6.42 Million EUR | -279.339% |
| Neovacs S.A. | 3.71 Million EUR | -556.686% |
| NFL Biosciences SA | 3.62 Million EUR | -573.271% |
| Plant Advanced Technologies SA | 6.78 Million EUR | -259.418% |
| Quantum Genomics Société Anonyme | 3.31 Million EUR | -636.441% |
| Sensorion SA | 13.22 Million EUR | -84.294% |
| Theranexus Société Anonyme | 5.01 Million EUR | -385.967% |
| TME Pharma N.V. | 2.78 Million EUR | -775.296% |
| Valbiotis SA | 13.7 Million EUR | -77.83% |
| TheraVet SA | 1.48 Million EUR | -1541.557% |
| Valerio Therapeutics Société anonyme | 20.46 Million EUR | -19.098% |
| argenx SE | 402.79 Million EUR | 93.948% |
| BioSenic S.A. | 32.26 Million EUR | 24.445% |
| Celyad Oncology SA | 9.97 Million EUR | -144.307% |
| DBV Technologies S.A. | 38.74 Million USD | 37.084% |
| Galapagos NV | 1.56 Billion EUR | 98.439% |
| Genfit S.A. | 105.92 Million EUR | 76.986% |
| GeNeuro SA | 20.13 Million EUR | -21.038% |
| Hyloris Pharmaceuticals SA | 8.61 Million EUR | -183.059% |
| Innate Pharma S.A. | 132.29 Million EUR | 81.573% |
| Inventiva S.A. | 101.59 Million EUR | 76.005% |
| MaaT Pharma SA | 22.46 Million EUR | -8.511% |
| MedinCell S.A. | 77.77 Million EUR | 68.655% |
| Nanobiotix S.A. | 95.74 Million EUR | 74.538% |
| Onward Medical N.V. | 25.69 Million EUR | 5.14% |
| Oryzon Genomics S.A. | 25.12 Million EUR | 2.979% |
| OSE Immunotherapeutics SA | 59.07 Million EUR | 58.738% |
| Oxurion NV | 19.73 Million EUR | -23.515% |
| Pharming Group N.V. | 228.28 Million EUR | 89.322% |
| Poxel S.A. | 53.9 Million EUR | 54.774% |
| GenSight Biologics S.A. | 34.72 Million EUR | 29.804% |
| Transgene SA | 26.51 Million EUR | 8.07% |
| Financière de Tubize SA | 123.65 Million EUR | 80.286% |
| UCB SA | 6.56 Billion EUR | 99.629% |
| Valneva SE | 341.14 Million EUR | 92.854% |
| Vivoryon Therapeutics N.V. | 4.54 Million EUR | -436.112% |